Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Neurizon appoints Elanco executive Justine Conway as observer on supervisory board
Neurizon has appointed Justine Conway, head of global business development at Elanco, as an observer on its supervisory board. The appointment follows the exclusive global licensing agreement for monepantel (active ingredient in NUZ-001) and is intended to secure access to animal safety and manufacturing data for clinical studies and regulatory approvals. Conway brings more than 20 years of experience in animal health, investment banking and M&A and will attend meetings without voting rights, while Neurizon advances late-stage development of NUZ-001 and plans to participate in the HEALEY-ALS platform study. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -777,63 | - |
| Beneficio neto | -3,14 M | - |
| EBITDA | -9,9 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 27,09 M € |
Número de acciones | 775,1 M |
Máximo/mínimo de 52 semanas | 0,10 € - 0,034 € |
| Dividendos | No |
Beta | 1,32 |
Ratio P/E | -3,23 |
Ratio PEG | 0,05 |
Ratio P/B | 3,37 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | NEURIZON THERAPEUTICS |
| CEO | Ben Dingle |
| Empleados | 36 |
Descubrir activos
Los accionistas de NEURIZON THERAPEUTICS también invierten en los siguientes activos
